Saturday 17 October 2026
Export PDEX’s income statement to Excel — free account
Pro-Dex, Inc.
PDEX Healthcare Medical Instruments & Supplies
Pro-Dex, Inc.’s revenue for fiscal 2026 (year ended June 2026) was $77.5 million, up 16.5% from fiscal 2025. In the quarter to June 2026, revenue grew 16.7%, EPS grew 143.2%, free cash flow fell 79.0% and total debt rose 43.5%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.
58.26
1.76
−2.93%
Follow PDEX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
13.84 | 13.28 | 11.09 | 9.87 |
+8 more quarters Free account |
P/S ratio |
2.44 | 2.11 | 1.73 | 1.57 | |
P/FCF ratio |
28.08 | 22.67 | 20.88 | 0.00 | |
P/Operating CF |
(691.88) | 96.28 | 35.00 | 47.80 | |
P/B ratio |
3.97 | 3.48 | 3.00 | 2.66 | |
Price to Tangible BV |
4.67 | 4.14 | 3.00 | 2.66 | |
EV/Sales |
2.49 | 2.15 | 1.72 | 1.54 | |
EV/EBITDA |
13.39 | 13.26 | 9.86 | 9.01 | |
EV/Operating CF |
26.62 | 21.87 | 19.22 | (86.18) | |
EV/FCF |
28.67 | 23.15 | 20.74 | (49.20) | |
Quick Ratio |
2.40 | 2.10 | 2.21 | 2.12 | |
Current Ratio |
4.10 | 3.67 | 4.03 | 3.73 | |
Net Debt/EBITDA |
1.00 | 0.96 | (0.23) | (0.56) | |
Debt/Assets |
17.80% | 19.08% | 12.86% | 13.42% | |
Debt/Equity |
0.28 | 0.32 | 0.19 | 0.21 | |
Asset Turnover |
1.14 | 1.07 | 1.18 | 1.18 | |
Operating CF/Net income |
(0.10) | 0.41 | 1.63 | 0.49 | |
Capex/Depreciation |
(0.50) | (0.31) | (0.22) | (0.31) | |
Interest Coverage |
13.07 | 15.39 | 23.11 | 15.55 | |
Research and Development Expense of Revenue |
4.98% | 4.15% | 3.93% | 4.14% | |
Selling, General and Administrative Expense of Revenue |
12.48% | 11.09% | 9.38% | 8.04% | |
Intangible Assets out of Total Assets |
0.10 | 0.10 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.87% | 0.93% | 0.88% | 0.87% | |
Graham Net Nets |
0.14 | 0.15 | 0.23 | 0.25 | |
Graham Number |
37.49 | 34.29 | 31.63 | 31.34 | |
Earnings Yield |
7.22% | 7.53% | 9.02% | 10.13% | |
Free Cash Flow Yield |
3.56% | 4.41% | 4.79% | (2.00%) | |
Revenue per Share |
6.33 | 6.23 | 5.74 | 5.68 | |
Operating CF per Share |
(0.08) | 0.51 | 1.10 | 0.71 | |
Capex per Share |
(0.06) | (0.03) | (0.02) | (0.03) | |
Free Cash Flow per Share |
(0.15) | 0.48 | 1.08 | 0.68 | |
Cash per Share |
2.90 | 3.43 | 2.71 | 3.23 | |
Shareholders Equity per Share |
14.77 | 14.12 | 12.81 | 12.73 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
14.77 | 14.12 | 12.81 | 12.73 | |
Free Cash Flow |
(0.48) | 1.52 | 3.50 | 2.21 | |
Working Capital |
40.27 | 39.07 | 36.99 | 37.12 | |
Capital Expenditures |
(0.20) | (0.11) | (0.07) | (0.10) | |
Net Current Asset Value |
26.37 | 23.93 | 28.56 | 27.94 | |
EV/EBIT |
14.84 | 14.86 | 10.94 | 10.06 | |
Capex to Sales |
0.01 | 0.01 | 0.00 | 0.01 | |
Price to Operating Income |
14.54 | 14.55 | 11.01 | 10.24 | |
| Other line items | |||||
Average Receivables |
19.66 | 17.82 | 18.31 | 15.90 | |
Average Payables |
4.44 | 5.60 | 4.90 | 4.20 | |
Average Inventory |
21.84 | 22.89 | 20.66 | 19.08 | |
Average Assets |
67.85 | 69.63 | 61.32 | 59.30 | |
Average Common Equity |
42.13 | 40.24 | 36.73 | 36.20 |
Columns are period end dates